Biodexa Pharmaceticals Stock Buy Hold or Sell Recommendation
| BDRX Stock | 1.90 0.09 4.52% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Biodexa Pharmaceticals is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Biodexa Pharmaceticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Biodexa Pharmaceticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Biodexa Pharmaceticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide. In addition, we conduct extensive research on individual companies such as Biodexa and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Biodexa |
Execute Biodexa Pharmaceticals Buy or Sell Advice
The Biodexa recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Biodexa Pharmaceticals. Macroaxis does not own or have any residual interests in Biodexa Pharmaceticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Biodexa Pharmaceticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Biodexa Pharmaceticals Trading Alerts and Improvement Suggestions
| Biodexa Pharmaceticals generated a negative expected return over the last 90 days | |
| Biodexa Pharmaceticals has high historical volatility and very poor performance | |
| Biodexa Pharmaceticals may become a speculative penny stock | |
| Biodexa Pharmaceticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 381 K. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 145 K. | |
| Biodexa Pharmaceticals generates negative cash flow from operations | |
| Biodexa Pharmaceticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP |
Biodexa Pharmaceticals Returns Distribution Density
The distribution of Biodexa Pharmaceticals' historical returns is an attempt to chart the uncertainty of Biodexa Pharmaceticals' future price movements. The chart of the probability distribution of Biodexa Pharmaceticals daily returns describes the distribution of returns around its average expected value. We use Biodexa Pharmaceticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Biodexa Pharmaceticals returns is essential to provide solid investment advice for Biodexa Pharmaceticals.
| Mean Return | -1.19 | Value At Risk | -11.63 | Potential Upside | 9.56 | Standard Deviation | 6.83 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Biodexa Pharmaceticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Biodexa Pharmaceticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (3.4M) | 2.5M | (7.2M) | 3.1M | 2.8M | 3.0M | |
| Free Cash Flow | (9.5M) | (6.3M) | (7.1M) | (7.1M) | (6.4M) | (6.7M) | |
| Depreciation | 1.2M | 403K | 343K | 283K | 254.7K | 242.0K | |
| Other Non Cash Items | 430K | (892K) | 454K | 397K | 357.3K | 603.6K | |
| Capital Expenditures | 209K | 320K | 62K | 263K | 236.7K | 380.6K | |
| Net Income | (22.2M) | (5.5M) | (7.7M) | (7.1M) | (6.4M) | (6.7M) | |
| End Period Cash Flow | 7.5M | 10.1M | 2.8M | 6.0M | 5.4M | 8.0M | |
| Investments | 2.6M | (278K) | (220K) | (265K) | (304.8K) | (320.0K) |
Biodexa Pharmaceticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Biodexa Pharmaceticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Biodexa Pharmaceticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Biodexa stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.03 | |
β | Beta against Dow Jones | 1.63 | |
σ | Overall volatility | 7.07 | |
Ir | Information ratio | -0.16 |
Biodexa Pharmaceticals Volatility Alert
Biodexa Pharmaceticals is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biodexa Pharmaceticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biodexa Pharmaceticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Biodexa Pharmaceticals Fundamentals Vs Peers
Comparing Biodexa Pharmaceticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Biodexa Pharmaceticals' direct or indirect competition across all of the common fundamentals between Biodexa Pharmaceticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Biodexa Pharmaceticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Biodexa Pharmaceticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Biodexa Pharmaceticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Biodexa Pharmaceticals to competition |
| Fundamentals | Biodexa Pharmaceticals | Peer Average |
| Return On Equity | -0.97 | -0.31 |
| Return On Asset | -0.38 | -0.14 |
| Operating Margin | (79.31) % | (5.51) % |
| Current Valuation | (4.73 M) | 16.62 B |
| Shares Outstanding | 668.59 K | 571.82 M |
| Shares Owned By Insiders | 8.82 % | 10.09 % |
| Shares Owned By Institutions | 29.85 % | 39.21 % |
| Number Of Shares Shorted | 46.95 K | 4.71 M |
| Price To Book | 0.12 X | 9.51 X |
| Price To Sales | 15.31 X | 11.42 X |
| Revenue | 381 K | 9.43 B |
| Gross Profit | 145 K | 27.38 B |
| EBITDA | (7.16 M) | 3.9 B |
| Net Income | (7.08 M) | 570.98 M |
| Total Debt | 464 K | 5.32 B |
| Book Value Per Share | 24.07 X | 1.93 K |
| Cash Flow From Operations | (6.83 M) | 971.22 M |
| Short Ratio | 0.03 X | 4.00 X |
| Earnings Per Share | (77.66) X | 3.12 X |
| Target Price | 18.6 | |
| Number Of Employees | 21 | 18.84 K |
| Beta | 1.5 | -0.15 |
| Market Capitalization | 1.27 M | 19.03 B |
| Total Asset | 10.54 M | 29.47 B |
| Retained Earnings | (144.77 M) | 9.33 B |
| Working Capital | 1.46 M | 1.48 B |
| Net Asset | 10.54 M |
Biodexa Pharmaceticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Biodexa . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Biodexa Pharmaceticals Buy or Sell Advice
When is the right time to buy or sell Biodexa Pharmaceticals? Buying financial instruments such as Biodexa Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Biodexa Pharmaceticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hedge Favorites Thematic Idea Now
Hedge Favorites
Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques. The Hedge Favorites theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hedge Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.